With this as a backdrop, yields moved lower along the curve in both Canada and the US in Q1. In contrast to last quarter, where prices were down significantly at the longer end, Q1 saw a partial reversal here with the iShares 20+ Year Treasury Bond ETF (TLT), an ETF that tracks longer dated US Treasuries, posting a total return of approximately 5% this quarter.
The first quarter of 2025 was another strong period for the Fund’s OPKO Health, Inc. (OPK) 3.75%’29 convertible bonds. During the quarter the company announced Q4 earnings. Highlights included the award of an additional $51 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) relating to COVID and flu treatment programs and they continued to reduce costs on the lab side of the business, targeting $20 million in savings in 2025. Repurchases of the converts and common shares continued during the period with $17 million and $16.5 million respectively repurchased over the quarter. Also, in Q1 the company announced the sale of further non-core BioReference assets to Labcorp for an additional $225 million, adding cash to the balance sheet and moving them closer to profitability in this segment. With a 1.2% weight in this position at the start of the period and price appreciation to the tune of ~26 points during the quarter, our holdings here provided a strong tailwind to performance in Q1.
New to the Fund are the 2.875%’28 convertible bonds of PPL Corporation (PPL) which we added in February 2025. PPL aligns with our general thesis relating to utilities. We believe PPL is undervalued in general, that coverage is robust in this space and, due to the essential nature of the services provided, profitability does not vary much with the economy. Against the current backdrop of elevated levels of economic uncertainty, having some exposure in this area makes sense to us.
PPL Corporation was founded in 1920 and is a regulated utility providing electricity and natural gas to millions of customers in Kentucky, Pennsylvania and Rhode Island. Both the company and this convertible bond are rated investment grade. Coverage is strong from several perspectives. EBITDA generated by the business covers interest owed greater than four times, PP&E along with our estimate of valuation both cover debt ~2 times and market cap of $25 billion provides a significant equity cushion of approximately $17 billion in debt. One year default probability resides at the relatively comforting level of approximately 0.0005%.
The company guided to grid improvements and rate base expansion they suggest could lead to 6%-8% EPS growth through at least 2028. Given what we have discussed above, the fact that the implied fair value of the converts, even at the current stock price, sits several points higher than where they currently trade, and also given the converts went into the money in February, we believe there is potential for upside here. Considering this and given the defensive nature of the industry in which the company operates, we like the risk to reward profile these converts offer.
Although drifting somewhat lower over the quarter, the US term premium remains positive and relatively elevated. As a result, and considering the economic uncertainty posed by the current policy environment, no significant changes were made to duration this quarter. The duration of the Fund was 4.7 at March 31.
High yield spreads rose marginally over the period however remain in relatively expensive territory. The exposure of the Fund to non-investment grade credit therefore remains below its maximum allowable with 21% of the Fund allocated here currently. Investment grade and cash accounted for 79% of the Fund at March 31.
The yield to maturity of the Fund was 3.99% at March 31.
Emily Wheeler, CFA
April 16, 2025